Oregon Public Employees Retirement Fund Acquires 287 Shares of LivaNova PLC (NASDAQ:LIVN)

Oregon Public Employees Retirement Fund boosted its holdings in shares of LivaNova PLC (NASDAQ:LIVNGet Rating) by 1.9% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,580 shares of the company’s stock after acquiring an additional 287 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in LivaNova were worth $791,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Comerica Bank grew its holdings in LivaNova by 15.2% during the 3rd quarter. Comerica Bank now owns 64,817 shares of the company’s stock worth $2,916,000 after acquiring an additional 8,533 shares during the last quarter. Sendero Wealth Management LLC lifted its position in shares of LivaNova by 118.7% in the 3rd quarter. Sendero Wealth Management LLC now owns 11,746 shares of the company’s stock worth $596,000 after purchasing an additional 6,376 shares during the period. Western Pacific Wealth Management LP acquired a new position in shares of LivaNova in the 3rd quarter worth approximately $44,000. Mirabella Financial Services LLP lifted its position in shares of LivaNova by 35.2% in the 3rd quarter. Mirabella Financial Services LLP now owns 47,904 shares of the company’s stock worth $2,432,000 after purchasing an additional 12,463 shares during the period. Finally, Sumitomo Mitsui Trust Holdings Inc. lifted its position in shares of LivaNova by 3.1% in the 3rd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 862,657 shares of the company’s stock worth $43,797,000 after purchasing an additional 26,168 shares during the period. 98.89% of the stock is owned by institutional investors.

Insider Transactions at LivaNova

In other news, CEO Damien Mcdonald sold 2,220 shares of the company’s stock in a transaction on Thursday, December 15th. The shares were sold at an average price of $54.56, for a total value of $121,123.20. Following the completion of the sale, the chief executive officer now owns 83,749 shares in the company, valued at approximately $4,569,345.44. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 0.38% of the company’s stock.

LivaNova Stock Down 1.3 %

LivaNova stock opened at $56.41 on Wednesday. The company has a quick ratio of 2.53, a current ratio of 2.96 and a debt-to-equity ratio of 0.45. The firm’s fifty day moving average is $54.95 and its 200 day moving average is $55.14. LivaNova PLC has a 12-month low of $41.82 and a 12-month high of $88.00. The company has a market capitalization of $3.02 billion, a PE ratio of -32.23 and a beta of 0.84.

LivaNova (NASDAQ:LIVNGet Rating) last released its quarterly earnings data on Wednesday, November 2nd. The company reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.01. LivaNova had a negative net margin of 9.14% and a positive return on equity of 9.28%. The firm had revenue of $252.60 million for the quarter, compared to the consensus estimate of $246.53 million. As a group, sell-side analysts predict that LivaNova PLC will post 1.73 EPS for the current fiscal year.

Analyst Ratings Changes

LIVN has been the topic of a number of recent analyst reports. Barclays initiated coverage on shares of LivaNova in a research report on Wednesday, December 21st. They issued an “equal weight” rating and a $62.00 price target on the stock. Needham & Company LLC dropped their price target on shares of LivaNova from $88.00 to $77.00 and set a “buy” rating on the stock in a research report on Wednesday, November 2nd. TheStreet downgraded shares of LivaNova from a “c-” rating to a “d” rating in a research report on Wednesday, October 19th. Piper Sandler dropped their price target on shares of LivaNova from $94.00 to $84.00 in a research report on Wednesday, November 2nd. Finally, The Goldman Sachs Group dropped their target price on shares of LivaNova from $73.00 to $63.00 and set a “buy” rating on the stock in a research report on Wednesday, November 23rd. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $79.50.

About LivaNova

(Get Rating)

LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the Cardiovascular and Neuromodulation segments. The Cardiovascular segment develops, produces, and sells cardiopulmonary products, heart valves, and circulatory support products.

Recommended Stories

Institutional Ownership by Quarter for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.